How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Alzheimer's Disease Therapeutics and Diagnostics Market
- By Therapeutic Approach: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Monoclonal Antibodies, Anti-Amyloid Agents, Tau Protein Inhibitors
- By Diagnostic Method: Biomarker Testing, Neuroimaging, Cognitive Assessments, Genetic Testing, CSF Analysis
- By Drug Class: Small Molecule Drugs, Biologics, Immunotherapies, Combination Therapies
- By Stage of Disease Targeted: Mild Cognitive Impairment (MCI) Stage, Early-Stage Alzheimer's, Moderate Alzheimer's, Severe Alzheimer's
- By End User: Hospitals, Specialty Clinics, Diagnostic Laboratories, Home Care Settings
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cholinesterase Inhibitors leads By Therapeutic Approach at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 12 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Alzheimer's Disease Therapeutics and Diagnostics Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Approach 5
Diagnostic Method 5
Drug Class 4
Stage of Disease Targeted 4
End User 4
Companies profiled
Eli Lilly and Company
Biogen Inc.
Roche Holding AG
Novartis AG
AC Immune SA
Axsome Therapeutics Inc.
Cassava Sciences Inc.
Anavex Life Sciences Corp.
TauRx Pharmaceuticals Ltd.
BioArctic AB
H. Lundbeck A/S
ACADIA Pharmaceuticals Inc.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Biogen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AC Immune SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Axsome Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Cassava Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Anavex Life Sciences Corp.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →TauRx Pharmaceuticals Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →BioArctic AB
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →H. Lundbeck A/S
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →ACADIA Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,855M by 2033 · 6.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cholinesterase Inhibitors41.4
- NMDA Receptor Antagonists16.7
- Monoclonal Antibodies13.8
- Anti-Amyloid Agents19.1
- Tau Protein Inhibitors9.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,799M → $2,737M · 5.4%
Europe$1,254M → $1,867M · 5.1%
Asia Pacific$1,145M → $1,788M · 5.7%
Latin America$708.6M → $1,082M · 5.4%
Middle East and Africa$545.1M → $958.5M · 7.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.202026
6.212027
6.242028
6.232029
6.262030
6.262031
6.282032
6.292033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Eli Lilly and Company10.9
- Biogen Inc.24.8
- Roche Holding AG9.7
- Novartis AG11.7
- AC Immune SA8.7
- Axsome Therapeutics Inc.6.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Approach22.8%
Diagnostic Method8.7%
Drug Class16.6%
Stage of Disease Targeted24.5%
End User27.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.5
- Europe22.1
- Asia Pacific21.2
- Latin America12.8
- Middle East and Africa11.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | 98 | 90 | 95 | 98 | 75 | 91 | 91 |
| Biogen Inc. | 88 | 84 | 70 | 68 | 70 | 72 | 75 |
| Roche Holding AG | 70 | 73 | 64 | 67 | 83 | 84 | 74 |
| Novartis AG | 63 | 70 | 80 | 76 | 72 | 81 | 74 |
| AC Immune SA | 61 | 59 | 77 | 75 | 73 | 59 | 67 |
| Axsome Therapeutics Inc. | 48 | 46 | 70 | 50 | 57 | 49 | 53 |
| Cassava Sciences Inc. | 45 | 63 | 57 | 55 | 58 | 46 | 54 |
| Anavex Life Sciences Corp. | 35 | 35 | 52 | 54 | 35 | 35 | 41 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Eli Lilly and Company
- Biogen Inc.
- Roche Holding AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Biogen Inc. | ◐ | ◐ | − | ◐ | ✓ | ◐ |
| Roche Holding AG | ◐ | ✓ | ✓ | − | ✓ | ◐ |
| Novartis AG | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| AC Immune SA | ◐ | − | ◐ | ◐ | ✓ | ◐ |
| Axsome Therapeutics Inc. | ◐ | − | ✓ | − | ◐ | − |
| Cassava Sciences Inc. | − | ◐ | − | ◐ | ◐ | − |
| Anavex Life Sciences Corp. | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Eli Lilly and Company91
2Biogen Inc.75
3Roche Holding AG74
4Novartis AG74
5AC Immune SA67
6Cassava Sciences Inc.54
7Axsome Therapeutics Inc.53
8Anavex Life Sciences Corp.41
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Eli Lilly and Company
Challenger4
Strong scale, closing on the leaders.
Biogen Inc.Roche Holding AGNovartis AGAC Immune SA
Niche3
Specialists in a single segment or region.
Axsome Therapeutics Inc.Cassava Sciences Inc.Anavex Life Sciences Corp.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Approach in North America, then scale across Alzheimer's Disease Therapeutics and Diagnostics Market — a $298M beachhead inside a $5.51B market.
Beachhead (SOM)$298Mobtainable near-term
Serviceable (SAM)$1.97Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Cholinesterase Inhibitors
Best fit — highest urgency & budget in Therapeutic Approach.
Economic buyer79 fit
NMDA Receptor Antagonists
Strong fit — clear ROI and a fast path to value.
End user67 fit
Monoclonal Antibodies
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Approach in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Diagnostic Method & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Drug Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Approach leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Alzheimer's Disease Therapeutics and Diagnostics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified26%
Evaluation12%
Closed-won6%
$9.0KCAC
$40KLTV
4.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Alzheimer's Disease Therapeutics and Diagnostics Market is a durable-growth opportunity — $5.60B by 2033, compounding at 7.0%.
TAM · 2025$3.27Btoday
TAM · 2033$5.60Bforecast
CAGR7.0%2027–2033
Cumulative$39.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.60BTotal addressable market
SAM$2.30BServiceable available market
SOM$389MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.0% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Approach.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Approach moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.60BLarge & growingTAM by 2033 at 7.0% CAGR
$2.30BServiceable nowreachable with today’s model
$389MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.37BBear4.5% CAGR
$5.60BBase7.0% CAGR
$7.17BBull9.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Diagnostic Method optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Alzheimer's Disease Therapeutics and Diagnostics Market — a $884M market by 2033. Plan: grow share from 8.8% to 13.8%.
Market size · 2033$884Mtotal addressable
Market CAGR8.2%2027–2033
Target share13.8%from 8.8% today
Revenue ambition$122Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 13.8% | Ahead |
| Revenue | $73M | $122M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 33.0% | 40.2% | At risk |
| Customer retention | 91.2% | 94.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Approach
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Diagnostic Method capability
A defensible second engine — invest in Diagnostic Method to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Approach share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Diagnostic Method
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $13M capacity & capability investment
- Greenlight bolt-on M&A in Diagnostic Method
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Approach leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Alzheimer's Disease Therapeutics and Diagnostics Market conversation — a $6.52B market you can size, segment and defend in minutes.
Market size · 2033$6.52Btotal opportunity
Growth6.9%CAGR to 2033
Addressable buyers1,536+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Approach
Goal Grow share in Therapeutic Approach
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 2 mopayback period
$76K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Eli Lilly and CompanyBiogen Inc.Roche Holding AGNovartis AGAC Immune SAAxsome Therapeutics Inc.Cassava Sciences Inc.Anavex Life Sciences Corp.+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Alzheimer's Disease Therapeutics and Diagnostics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Alzheimer's Disease Therapeutics and Diagnostics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →HIV Drugs Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportWound Healing Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportWound Cleaning Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportMyocardial Infarction Drugs Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportAlthaea Officinalis Root Extract Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportHeart Failure Drugs Market
Heart Failure Drugs Market is valued at USD 18.85 Billion in 2025 and is expected to reach USD …
$18.9B market · 2025 base year
View reportH1N1 Vaccines Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportLong-Term Acute Care Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportLiniments And Rubs Market
Market size, share, segmentation and regional forecast.
$877M market · 2025 base year
View reportBreakthrough Therapy Drugs Market
Breakthrough Therapy Drugs Market is valued at USD 18.2 Billion in 2025 and is expected to reac…
$18.2B market · 2025 base year
View reportBladder Cancer Treatment Drugs Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportAlternative to Antibiotics Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.